Tempest Therapeutics

TPST - Tempest Therapeutics • Financials

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2019
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0
-29
-
0%
L
27
L
-29
-
-30
-0
36
-30
0
0
-
-
0
-42
-
0%
L
19
L
-24
-
-38
-0
25
-39
0
0
-
-
0
-26
-
0%
L
7
L
-8
-
-30
0
4
-30
0
0
-
-